<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35509067</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1479-5876</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>20</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>04</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of translational medicine</Title>
          <ISOAbbreviation>J Transl Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>TPI1 activates the PI3K/AKT/mTOR signaling pathway to induce breast cancer progression by stabilizing CDCA5.</ArticleTitle>
        <Pagination>
          <StartPage>191</StartPage>
          <MedlinePgn>191</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">191</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-022-03370-2</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Triosephosphate isomerase 1 (TPI1), as a key glycolytic enzyme, is upregulated in multiple cancers. However, expression profile and regulatory mechanism of TPI1 in breast cancer (BRCA) remain mysterious.</AbstractText>
          <AbstractText Label="METHODS">Western blotting and immunohistochemistry (IHC) assays were used to investigate the expression of TPI1 in BRCA specimens and cell lines. TPI1 correlation with the clinicopathological characteristics and prognosis of 362 BRCA patients was analyzed using a tissue microarray. Overexpression and knockdown function experiments in cells and mice models were performed to elucidate the function and mechanisms of TPI1-induced BRCA progression. Related molecular mechanisms were clarified using co-IP, IF, mass spectrometric analysis, and ubiquitination assay.</AbstractText>
          <AbstractText Label="RESULTS">We have found TPI1 is highly expressed in BRCA tissue and cell lines, acting as an independent indicator for prognosis in BRCA patients. TPI1 promotes BRCA cell glycolysis, proliferation and metastasis in vitro and in vivo. Mechanistically, TPI1 activates phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway to regulate epithelial-mesenchymal transformation (EMT) and aerobic glycolysis, which is positively mediated by cell division cycle associated 5 (CDCA5). Moreover, TPI1 interacts with sequestosome-1 (SQSTM1)/P62, and P62 decreases the protein expression of TPI1 by promoting its ubiquitination in MDA-MB-231 cells.</AbstractText>
          <AbstractText Label="CONCLUSIONS">TPI1 promotes BRCA progression by stabilizing CDCA5, which then activates the PI3K/AKT/mTOR pathway. P62 promotes ubiquitin-dependent proteasome degradation of TPI1. Collectively, TPI1 promotes tumor development and progression, which may serve as a therapeutic target for BRCA.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Jin</LastName>
            <ForeName>Xiaoying</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150040, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Wang</LastName>
            <ForeName>Dandan</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150040, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Lei</LastName>
            <ForeName>Mengxia</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150040, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guo</LastName>
            <ForeName>Yan</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150040, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cui</LastName>
            <ForeName>Yuqing</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150040, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Fengzhi</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150040, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Weiling</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150040, China. sunweiling@hrbmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chen</LastName>
            <ForeName>Xuesong</ForeName>
            <Initials>X</Initials>
            <Identifier Source="ORCID">0000-0003-4332-7559</Identifier>
            <AffiliationInfo>
              <Affiliation>The Fourth Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, 150040, China. cxs1978@ems.hrbmu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>04</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Transl Med</MedlineTA>
        <NlmUniqueID>101190741</NlmUniqueID>
        <ISSNLinking>1479-5876</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D048868">Adaptor Proteins, Signal Transducing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C500695">CDCA5 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018797">Cell Cycle Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.137</RegistryNumber>
          <NameOfSubstance UI="D058539">Phosphatidylinositol 3-Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D048868" MajorTopicYN="N">Adaptor Proteins, Signal Transducing</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018797" MajorTopicYN="N">Cell Cycle Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002465" MajorTopicYN="N">Cell Movement</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="N">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058539" MajorTopicYN="N">Phosphatidylinositol 3-Kinase</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019869" MajorTopicYN="Y">Phosphatidylinositol 3-Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">CDCA5</Keyword>
        <Keyword MajorTopicYN="Y">Epithelial–mesenchymal transformation (EMT)</Keyword>
        <Keyword MajorTopicYN="Y">Glycolysis</Keyword>
        <Keyword MajorTopicYN="Y">PI3K/AKT/mTOR</Keyword>
        <Keyword MajorTopicYN="Y">TPI1</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no potential conflicts of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>9</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>5</Day>
          <Hour>0</Hour>
          <Minute>9</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35509067</ArticleId>
        <ArticleId IdType="pmc">PMC9066866</ArticleId>
        <ArticleId IdType="doi">10.1186/s12967-022-03370-2</ArticleId>
        <ArticleId IdType="pii">10.1186/s12967-022-03370-2</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Gong Z, Chen M, Ren Q, Yue X, Dai Z. Fibronectin-targeted dual-acting micelles for combination therapy of metastatic breast cancer. Signal Transduct Target Ther. 2020;5(1):12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7005157</ArticleId>
            <ArticleId IdType="pubmed">32296050</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33538338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Heiden MG. Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov. 2011;10(9):671–684.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21878982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wintzell M, Löfstedt L, Johansson J, Pedersen AB, Fuxe J, Shoshan M. Repeated cisplatin treatment can lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3-bromopyruvate. Cancer Biol Ther. 2014;13(14):1454–1462.</Citation>
        </Reference>
        <Reference>
          <Citation>Abdel-Wahab AF, Mahmoud W, Al-Harizy RM. Targeting glucose metabolism to suppress cancer progression: prospective of anti-glycolytic cancer therapy. Pharmacol Res. 2019;150:104511.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31678210</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">13298683</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He CL, Bian YY, Xue Y, Liu ZX, Zhou KQ, Yao CF, Lin Y, Zou HF, Luo FX, Qu YY, et al.  Pyruvate kinase M2 activates mTORC1 by phosphorylating AKT1S1. Sci Rep. 2016;6:21524.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4753445</ArticleId>
            <ArticleId IdType="pubmed">26876154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu X, Li S. Non-metabolic functions of glycolytic enzymes in tumorigenesis. Oncogene. 2017;36(19):2629–2636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27797379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 2005;5(12):921–929.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16341083</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martini M, De Santis MC, Braccini L, Gulluni F, Hirsch E. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46(6):372–383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">24897931</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong SW, Li RL, Zhao MY, Zhen Y, Yu XL, et al.  Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol. 2015;8:22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4359783</ArticleId>
            <ArticleId IdType="pubmed">25887760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pekel G, Ari F. Therapeutic targeting of cancer metabolism with triosephosphate isomerase. Chem Biodivers. 2020;17(5):e2000012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32180338</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen T, Huang Z, Tian Y, Lin B, He R, Wang H, Ouyang P, Chen H, Wu L. Clinical significance and prognostic value of triosephosphate isomerase expression in gastric cancer. Medicine. 2017;96(19):e6865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5428617</ArticleId>
            <ArticleId IdType="pubmed">28489783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ansari-Lari MA, Muzny DM, Lu J, Lu F, Lilley CE, Spanos S, Malley T, Gibbs RA. A gene-rich cluster between the CD4 and triosephosphate isomerase genes at human chromosome 12p13. Genome Res. 1996;6(4):314–326.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8723724</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maquat LE, Chilcote R, Ryan PM. Human triosephosphate isomerase cDNA and protein structure. Studies of triosephosphate isomerase deficiency in man. J Biol Chem. 1985;260(6):3748–3753.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">2579079</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu WL, Yu G, Dong H, Chen K, Xie J, Yu H, Ji Y, Yang GS, Li AJ, Cong WM, et al.  Proteomics analysis identified TPI1 as a novel biomarker for predicting recurrence of intrahepatic cholangiocarcinoma. J Gastroenterol. 2020;55(12):1171–1182.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33089343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang F, Xiao ZQ, Zhang XZ, Li C, Zhang PF, Li MY, Chen Y, Zhu GQ, Sun Y, Liu YF, et al.  Identification of tumor antigens in human lung squamous carcinoma by serological proteome analysis. J Proteome Res. 2007;6(2):751–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17269731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang XZ, Xiao ZF, Li C, Xiao ZQ, Yang F, Li DJ, Li MY, Li F, Chen ZC. Triosephosphate isomerase and peroxiredoxin 6, two novel serum markers for human lung squamous cell carcinoma. Cancer Sci. 2009;100(12):2396–2401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19737146</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen WZ, Pang B, Yang B, Zhou JG, Sun YH. Differential proteome analysis of conditioned medium of BPH-1 and LNCaP cells. Chin Med J. 2011;124(22):3806–3809.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22340245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamesa MS, Kuramitsu Y, Fujimoto M, Maeda N, Nagashima Y, Tanaka T, Yamamoto S, Oka M, Nakamura K. Detection of autoantibodies against cyclophilin A and triosephosphate isomerase in sera from breast cancer patients by proteomic analysis. Electrophoresis. 2009;30(12):2168–2181.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19582718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Desmetz C, Bibeau F, Boissiere F, Bellet V, Rouanet P, Maudelonde T, Mange A, Solassol J. Proteomics-based identification of HSP60 as a tumor-associated antigen in early stage breast cancer and ductal carcinoma in situ. J Proteome Res. 2008;7(9):3830–3837.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18683965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li L, Chen SH, Yu CH, Li YM, Wang SQ. Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J Proteome Res. 2008;7(2):611–620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18161940</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang H, Ma N, Shang Y, Zhou W, Chen T, Guan D, Li J, Wang J, Zhang E, Feng Y, et al.  Triosephosphate isomerase 1 suppresses growth, migration and invasion of hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2017;482(4):1048–1053.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27908734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vasaikar SV, Straub P, Wang J, Zhang B. LinkedOmics: analyzing multi-omics data within and across 32 cancer types. Nucleic Acids Res. 2018;46(D1):D956–D963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5753188</ArticleId>
            <ArticleId IdType="pubmed">29136207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, Wang D, Lei M, Gao J, Cui Y, Jin X, Yu Q, Jiang Y, Guo Y, Liu Y, et al.  GABARAP suppresses EMT and breast cancer progression via the AKT/mTOR signaling pathway. Aging. 2021;13(4):5858–5874.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7950252</ArticleId>
            <ArticleId IdType="pubmed">33591943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mars N, Widen E, Kerminen S, Meretoja T, Pirinen M, Della Briotta Parolo P, Palta P, FinnGen, Palotie A, Kaprio J, et al.  The role of polygenic risk and susceptibility genes in breast cancer over the course of life. Nat Commun. 2020;11(1):6383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7736877</ArticleId>
            <ArticleId IdType="pubmed">33318493</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lawrence MSSP, Polak P, Kryukov GV, Cibulskis K, et al.  Mutational heterogeneity in cancer and the search for new cancer. Nature. 2013;499(7457):214–218.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3919509</ArticleId>
            <ArticleId IdType="pubmed">23770567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Talhouet S, Peron J, Vuilleumier A, Friedlaender A, Viassolo V, Ayme A, et al.  Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. Sci Rep. 2020;10(1):7073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7184602</ArticleId>
            <ArticleId IdType="pubmed">32341426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schliebs W, Thanki N, Jaenicke R, Wierenga RK, et al.  A double mutation at the tip of the dimer interface loop of triosephosphate isomerase generates active monomers with reduced stability. Biochemistry. 1997;36(32):9655–9662.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9245397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez-Almazán C, Arreola R, Rodríguez-Larrea D, Torres-Larios A, et al.  Structural basis of human triosephosphate isomerase deficiency: mutation E104D is related to alterations of a conserved water network at the dimer interface. J Biol Chem. 2008;283(34):23254–23263.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18562316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seigle JL, Celotto AM, Palladino MJ. Degradation of functional triose phosphate isomerase protein underlies sugarkill pathology. Genetics. 2008;179(2):855–862.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2429879</ArticleId>
            <ArticleId IdType="pubmed">18458110</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20–29.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16368868</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>La Belle FA, Calhoun BC, Sharma A, Chang JC, Almasan A, Schiemann WP. Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nat Commun. 2019;10(1):3668.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6694140</ArticleId>
            <ArticleId IdType="pubmed">31413316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leslie PL, Chao YL, Tsai YH, Ghosh SK, Porrello A, Van Swearingen AED, Harrison EB, Cooley BC, Parker JS, Carey LA, et al.  Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes. Nat Commun. 2019;10(1):4192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6744422</ArticleId>
            <ArticleId IdType="pubmed">31519896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Santa-Maria CA, Gradishar WJ. Changing treatment paradigms in metastatic breast cancer: lessons learned. JAMA Oncol. 2015;1(4):528–534.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26181262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dongre A, Weinberg RA. New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20(2):69–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">30459476</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell. 2007;12(1):9–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17613433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LL. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 2012;30(23):2919–2928.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3410405</ArticleId>
            <ArticleId IdType="pubmed">22778315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tian H, Lian R, Li Y, Liu C, Liang S, Li W, Tao T, Wu X, Ye Y, Yang X, et al.  AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent Vimentin degradation. Nat Commun. 2020;11(1):5127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7550350</ArticleId>
            <ArticleId IdType="pubmed">33046716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fu G, Xu Z, Chen X, Pan H, Wang Y, Jin B. CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k/AKT/mTOR pathway activation. J Cancer. 2020;11(9):2408–2420.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7066009</ArticleId>
            <ArticleId IdType="pubmed">32201512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schmitz J, Watrin E, Lenart P, Mechtler K, Peters JM. Sororin is required for stable binding of cohesin to chromatin and for sister chromatid cohesion in interphase. Curr Biol. 2007;17(7):630–636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17349791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen H, Chen J, Zhao L, Song W, Xuan Z, Chen J, Li Z, Song G, Hong L, Song P, et al.  CDCA5, transcribed by E2F1, promotes oncogenesis by enhancing cell proliferation and inhibiting apoptosis via the AKT pathway in hepatocellular carcinoma. J Cancer. 2019;10(8):1846–1854.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC6547986</ArticleId>
            <ArticleId IdType="pubmed">31205541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nguyen MH, Koinuma J, Ueda K, Ito T, Tsuchiya E, Nakamura Y, Daigo Y. Phosphorylation and activation of cell division cycle associated 5 by mitogen-activated protein kinase play a crucial role in human lung carcinogenesis. Cancer Res. 2010;70(13):5337–5347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20551060</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mueller TD, Feigon J. Solution structures of UBA domains reveal a conserved hydrophobic surface for protein–protein interactions. J Mol Biol. 2002;319(5):1243–1255.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12079361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol. 2004;24(18):8055–8068.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC515032</ArticleId>
            <ArticleId IdType="pubmed">15340068</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koh A, Park D, Jeong H, Lee J, Lee MN, Suh PG, Ryu SH. Regulation of C1-Ten protein tyrosine phosphatase by p62/SQSTM1-mediated sequestration and degradation. Cell Signal. 2014;26(11):2470–2480.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25101860</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li S-S, Ling-Zhi Xu, Zhou W, Yao S, Wang C-L, Xia J-L, Wang H-F, Kamran M, Xue X-Y, Dong L. p62/SQSTM1 interacts with vimentin to enhance breast. Carcinogenesis. 2017;38(11):1092–1103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5862327</ArticleId>
            <ArticleId IdType="pubmed">28968743</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
